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Abstract
Neuroendocrine prostate cancer (NEPC) is a more aggressive subtype of castration-resistant prostate cancer (CRPC).
Although it is well established that PHF8 can enhance prostate cancer cell proliferation, whether PHF8 is involved in
prostate cancer initiation and progression is relatively unclear. By comparing the transgenic adenocarcinoma of the
mouse prostate (TRAMP) mice with or without Phf8 knockout, we systemically examined the role of PHF8 in prostate
cancer development. We found that PHF8 plays a minimum role in initiation and progression of adenocarcinoma.
However, PHF8 is essential for NEPC because not only is PHF8 highly expressed in NEPC but also animals without
Phf8 failed to develop NEPC. Mechanistically, PHF8 transcriptionally upregulates FOXA2 by demethylating and
removing the repressive histone markers on the promoter region of the FOXA2 gene, and the upregulated FOXA2
subsequently regulates the expression of genes involved in NEPC development. Since both PHF8 and FOXA2 are
highly expressed in NEPC tissues from patients or patient-derived xenografts, the levels of PHF8 and FOXA2 can
either individually or in combination serve as NEPC biomarkers and targeting either PHF8 or FOXA2 could be poten-
tial therapeutic strategies for NEPC treatment.
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great
Britain and Ireland.
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Introduction
Neuroendocrine prostate cancer (NEPC) is a more aggres-
sive subtype of castration-resistant prostate cancer (CRPC)
and therefore patients with NEPC have an extremely poor
overall survival [1]. Although only a small percentage
(0.5–2%) of primary prostate cancers are NEPC [2], treat-
ments such as androgen deprivation therapy (ADT), espe-
cially with the use of the second-generation anti-androgen
drugs enzalutamide and abiraterone, often induce neu-
roendocrine differentiation and lead to up to 30% of
metastatic castration-resistant tumors as NEPC [3].
Compared with the other subtypes of prostate cancer,
NEPC expresses specific neuroendocrine markers
including synaptophysin (SYP), chromogranin A (CgA),
and neuronal-specific enolase (NSE), with concurrent
absence of androgen receptor (AR) and prostate-specific
antigen (PSA) [4]. Due to the limited understanding of
the molecular mechanisms in NEPC development and pro-
gression, there are few options for NEPC treatment except
platinum-based chemotherapies.
Although the origin of NEPC cells remains debated,
different molecular mechanisms might be involved in
NEPC development. Previous studies suggest that
NEPCmay originate from neuroendocrine cells [5], can-
cer stem cells [6], p63-positive basal cells [7] or CRPC
adenocarcinoma cells via trans-differentiation [8,9],
especially under the pressure of ADT [10,11]. There is
compelling evidence that loss of tumor suppressors such
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as RB1 and p53 is required to develop a neuroendocrine
lineage [12]. In addition, several transcription factors
including MYCN [13], BRN2 [14], FOXA2 [15], and
ASCL1 [16], as well as epigenetic regulators such as
REST [17] and EZH2 [18], have been implicated in
NEPC development. Of note, FOXA2, a member of
the FOXA family of the Forkhead box transcription fac-
tors, has been implicated as a specific marker for small
cell NEPC [19,20]. Furthermore, results from research
using the transgenic adenocarcinoma of the mouse pros-
tate (TRAMP) mouse model indicate that FOXA2 func-
tions together with HIF1α to drive a transcriptional
program essential for NEPC development [15], thus
establishing FOXA2 as a driving factor for NEPC.
PHF8 (plant homeodomain finger-containing protein
8), also known as KDM7B, is a histone demethylase.
The N-terminal plant homeodomain (PHD) domain of
PHF8 is responsible for recognizing/binding di- and
tri-methylated histone H3 lysine 4 (H3K4me2/3), which
are often enriched at transcription start sites, whereas its
C-terminal JmjC domain possesses histone demethylase
activities, catalyzing the removal of methyl group from
H3K9me1/2, H3K27me2, and H4K20me1 [21]. PHF8
has been implicated in promoting different malignancies
including prostate cancer [22], esophagus cancer [23],
and lung cancer [24]. We previously used a prostate can-
cer cell line-based model to demonstrate that PHF8, by
serving as an AR coactivator, can enhance CRPC pro-
gression [25]. In this study, we used the well-established
TRAMP mouse model with Phf8 knockout to demon-
strate the critical role of PHF8 and the underlying molec-
ular mechanism in PHF8-mediated NEPC development.
Materials and methods
Animals and experimental procedures
All experiments involving animals were performed in
accordance with international laws (EEC Council Direc-
tive 86/609, OJ L 358. 1, 12 December 1987; Guide for
the Care and Use of Laboratory Animals, United States
National Research Council, 1996) and approved by the
Institutional Animal Care and Use Committee of Army
Medical University. Transgenic TRAMP (transgenic
adenocarcinoma of the mouse prostate, C57BL/6) and
Phf8 knockout mice at the age of 5–6 weeks were
obtained from the Model Animal Research Center of
Nanjing University (Nanjing, Jiangsu, PR China). The
animals were housed and crossed in the Experimental
Animal Center of Daping Hospital, Army Medical Uni-
versity (Chongqing, PR China). By crossing Phf8
knockout female mice (Phf8X−/−) with TRAMP male
mice, Phf8 knockout TRAMP mice (Phf8-KO;
TRAMP) were obtained. Mice were sacrificed at weeks
12 (n = 5 per group), 25 (n = 5 per group), 37 (n = 8
per group), and 42 (n = 7 per group).
Histologic analysis
The prostate was dissected from sacrificed animals and
fixed in 10% formalin for 24 h, then paraffin-embedded
for hematoxylin and eosin (H&E) staining. Histologic
analysis of prostate lesions including NEPC was con-
ducted essentially as described previously [26]. In brief,
the slides were observed using a light microscope
(BX53; Olympus, Tokyo, Japan), photographed, and
the histologic features were classified by two certified
pathologists double-blindly (QM and HX) based on the
following specifications: (1) normal tissue (NT);
(2) low-grade PIN (prostatic intraepithelial neoplasia,
LGPIN); (3) high-grade PIN (HGPIN); (4) well-
differentiated adenocarcinoma (WD-Adeno); and
(5) undifferentiated adenocarcinoma (UD-Adeno, which
was categorized as an NEPC lesion according to the
pathological characteristics: pleomorphism, high
nuclear/cytoplasmic ratio, and loss of glandular differen-
tiation). For each prostate, ten random fields were cap-
tured at 10× magnification, which were further divided
into four quadrants. In each quadrant, the most advanced
histologic feature was used for histological classifica-
tion. Thus, the numbers of each subtype of lesions in
each experimental group were established, and the per-
centages of different subtypes of lesions were compared
among different experimental groups.
Cell lines, reagents, and patient-derived xenograft
(PDX) tissue lines
The prostate cancer cell lines PC-3 and LNCaP were
obtained from Cell Bank of Shanghai Institutes for Bio-
logical Sciences (Chinese Academy of Sciences, Shang-
hai, PR China), and NE1.3 cells were kindly provided
by Dr Wenliang Li (University of Texas Health Science
Center at Houston; MD Anderson Cancer Center UT
Health Graduate School of Biomedical Sciences). All
cells were grown in themedium recommended by the dis-
tributors. PDX tissue lines (LTL-545 and LTL-313HR)
were kindly provided by Professor Yuzhuo Wang
(Living Tumor Laboratory, http://livingtumorlab.com/).
The specimens were transplanted subcutaneously into
NPG mice (Beijing Vitalstar Biotechnology, Beijing, PR
China). The transplanted tumors were dissected from the
sacrificed mice, fixed in 10% formalin, and paraffin-
embedded for immunostaining and examination.
siRNA transfections and shRNA infections
siRNAs (Guangzhou RiboBio Co, Ltd, Guangzhou,
Guangdong Province, PR China) were used to transiently
knock down PHF8 in cells with scrambled siRNA as the




GATGGAAGACGAATTT). In general, siRNAs
(150 nM) were transfected into 5 million cells using
Lipo2000 according to the manufacturer’s protocol
(Thermo Fisher, Waltham, MA, USA) and the cells
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were analyzed 48 h post-transfection. To increase
knockdown efficiency, four respective specific siRNAs
were pooled for transfection. For the stable knockdown
by using shRNA infections, PHF8 shRNA (targeted
sequence: GCTCTTTCCAGAAAGCAAAGT) was
cloned into pYr-LVsh-EGFP-Puro vector (Changsha
Yingrun Biotechnology Co, Ltd, Changsha, Hunan
Province, PR China). PC-3, LNCaP, and NE1.3 cells
were infected with EV (empty vector as control) or
PHF8 shRNA lentivirus, and puromycin was used to
select the infected cells.
In vivo tumorigenesis assay
PC-3 cells (1 × 107 per 50 μl) with (shPHF8) or without
(EV) infection of PHF8 shRNA were mixed with Matri-
gel (1:1) and then injected subcutaneously into the flanks
of 6- to 7-week-old nude mice. The sizes of the tumors
were recorded every 2 days and the volumes were calcu-
lated using the formula length × width2/2. The final
tumor size was estimated using the whole-body fluores-
cence as the pYr-LVsh-Puro vector contained the EGFP
sequence and the xenograft tumors derived from EV and
shPHF8 PC-3 cells could be detected using a whole-
body fluorescence imaging system (Maestro in vivo
Imaging System; PerkinElmer, Waltham, MA, USA).
The transplanted tumors were dissected, weighed, fixed
in 10% formalin, and paraffin-embedded for immunos-
taining examination. To assess any difference in lung
metastasis, EV and shPHF8 PC-3 cells (3 × 106 per
50 μl) were injected into the tail vein of 6- to 7-week-
old nude mice and the tumors were allowed to grow for
19 days before mice were sacrificed. The lungs were dis-
sected, rinsed with PBS, and paraffin-embedded for
sectioning.
Patients and tissue samples
All procedures involving human participants were car-
ried out in accordance with the ethical standards of the
institutional research committee and with the 1964 Dec-
laration of Helsinki and its later amendments or compa-
rable ethical standards. All patient samples were
collected by the Department of Pathology with approval
from the Research Ethics Committee of Daping Hospi-
tal, ArmyMedical University, and written informed con-
sent was obtained from each patient. To estimate the role
of PHF8 in ADT-induced NED, a cohort of seven
patients was specifically selected from our database.
All these patients underwent ADT and abiraterone, enza-
lutamide or docetaxel treatment after prostate puncture
biopsy, and NEPC or NE regions were identified after
the therapy. The clinical information of these patients
is shown in supplementary material, Table S1. To deter-
mine the levels of PHF8 and FOXA2 in adenocarci-
noma, CRPC-Adeno, and NEPC tissues, an
adenocarcinoma tissue microarray (TMA) described
previously [27], a PDX tissue microarray kindly pro-
vided by Professor Yuzhuo Wang, as well as another
six CRPC-Adeno tissues (supplementary material,
Table S2) and the above-mentioned seven NEPC or
NED tissues from our cohort were used. In total, 59 sam-
ples with adenocarcinoma, 13 samples with CRPC-
Adeno, and 10 samples with NEPC or NED were
included.
Immunohistochemical staining
The embedded specimens were sectioned, mounted onto
glass slides, and then immunostained as described previ-
ously [27]. Primary antibodies against AR (ab108347,
1:200; Abcam, Cambridge, MA, USA), PSA (sc-7316,
1:50; Santa Cruz Biotechnology, Dallas, TX, USA),
SYP (17785-1-AP, 1:400; Proteintech, Rosemont, IL,
USA), CD56 (14255-1-AP, 1:600; Proteintech), CgA
(60135-1-lg, 1:600; Proteintech), PHF8 (ab36068,
1:200; Abcam), Large-T (554149, 1:100; BD, Lake
Franklin, NJ, USA), and FOXA2 (sc374376, 1:50; Santa
Cruz Biotechnology) were used. The staining intensities
were scored as described previously [28] by certified
pathologists (QM and HX) and imaged using a light
microscope (BX53; Olympus, Tokyo, Japan).
Immunofluorescence staining
Immunofluorescence staining for CK5 and CK18 or
PHF8 and FOXA2 was carried out on formalin-fixed,
paraffin-embedded sections. The sections were incu-
bated with primary antibodies against CK5 (ab52635,
rabbit, Abcam, 1:400), CK18 (66187-1-lg, mouse, Pro-
teintech, 1:200), PHF8 (ab36068, rabbit, Abcam,
1:200), and FOXA2 (sc374376, mouse, Santa Cruz Bio-
technology, 1:50). Secondary antibodies used for detec-
tion were goat anti-rabbit antibodies conjugated to Alexa
Fluor 488 (1:200; Zhongshan Gold Bridge Biotechnol-
ogy, Beijing, PR China) and goat anti-mouse antibodies
conjugated to Alexa Fluor 594 (1:200; Zhongshan Gold
Bridge Biotechnology). The sections were counter-
stained with DAPI for 15 min (KGA215; KeyGenBio-
TECH, Nanjing, Jiangsu Province, PR China) at 37 C,
and images were obtained using confocal microscopy
(LSM700; Zeiss, Oberkochen, Germany).
Estimation of cell number
PC-3, LNCaP, and NE1.3 cells with or without infection
with PHF8 shRNA and/or FOXA2 plasmid were seeded
into 96-well plates. Cell numbers were evaluated using
the Cell Counting Kit-8 (CCK-8) assay at the indicated
time points. In brief, the culture medium was aspirated
and the cells were rinsed with PBS, followed by applica-
tion of CCK-8 reagent (10 μl per well) for 2 h at 37 C.
Absorbance at 450 nm was measured spectrophotomet-
rically (Bio-Rad, Hercules, CA, USA).
Clonogenic assays
PC-3 cells with or without infection of PHF8 shRNA
and LNCaP cells with or without PHF8 overexpression
were seeded in six-well plates with 1000 (PC-3) or
2000 (LNCaP) cells per well, treated as indicated, and
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incubated at 37 C for 14 days with the medium changed
every 7 days. At the end of the experiment, cells were
fixed with methanol, stained with crystal violet, and the
numbers of colonies were counted.
Transwell assays
To assess cell migration and invasion in vitro, we used
24-well Transwell chambers with or without Matrigel.
PC-3 and LNCaP cells with or without PHF8 shRNA
were trypsinized and seeded into the top chamber at a
density of 5 × 104 cells per well in 200 μl of Dulbecco’s
modified Eagle’s medium. The bottom chambers con-
tained 800 μl of medium (10% fetal calf serum). After
incubation at 37 C for 24 h (PC-3) or 48 h (LNCaP),
cells attached to the top of the membrane were carefully
removed with a cotton swab, whereas cells in the bottom
chamber were fixed with 10% formalin and stained with
crystal violet for 3 min at room temperature and counted.
Wound healing assay
PC-3 cells with or without shRNA against PHF8 were
seeded into a six-well plate and grown for 24 h. A
scratch was made in the confluent cell monolayer using
a sterile 10-μl pipette tip and the cells were rinsed once
with PBS and then incubated in a serum-free medium.
Images of the scratches were captured at different time
points (0, 24, and 48 h) with an inverted microscope
(CK40F200; Olympus).
Luciferase assay
Cells in 12-well plates were transfected with 1 μg of
FOXA2-Luc vector, 100 ng of Renilla luciferase vector,
and plasmid expressing PHF8, using Lipofectamine.
Transfected cells were cultured for 48 h and the cell
lysates were used for a Dual-luciferase Assay (E1910;
Promega, Madison, WI, USA). Ten microliters of cell
lysates was loaded into a 96-well plate and luciferase
activity was measured using a Veritas Microplate
Luminometer (Thermo Fisher, Waltham, MA, USA)
according to the manufacturer’s instructions. Renilla
luciferase activity was used to normalize transfection
efficiency.
Immunoblotting
Cell lysates were separated by SDS-PAGE, followed by
immunoblotting assays as described previously [27,28]
with antibodies against PHF8 (ab36068, 1:1000;
Abcam, Cambridge, MA, USA), SYP (17785-1-AP,
1:2000; Proteintech, Rosemont, IL, USA), CgA
(60135-1-lg, 1:600; Proteintech), CD56 (14255-1-AP,
1:2000; Proteintech), FOXA2 (ab256493, 1:1000;
Abcam), and β-actin (3700s, 1:5000; Cell Signaling
Technology, Boston, MA, USA).
Chromatin immunoprecipitation (ChIP) assays and
quantitative polymerase chain reaction (qPCR)
ChIP assays were performed using a magnetic ChIP kit
according to the manufacturer’s instructions (53009;
Active Motif, Carlsbad, CA, USA). In brief, cells were
fixed by 1% formaldehyde; chromatins were fragmented
by enzymatic digestion. Antibodies against PHF8
(ab36068; Abcam), H3K9me1 (ab8896; Abcam),
H3K9me2 (ab1220; Abcam), H3K27me2 (ab24684;
Abcam), and H4K20me1 (ab9051; Abcam) were used
for immunoprecipitation. After washing and reverse-
crosslinking, the precipitated DNA was purified and
amplified by qPCR. Extracted RNA was reverse-
transcribed into cDNA and qPCR was performed using
the SYBR Green Master Mix (Invitrogen, Carlsbad,
CA, USA) in the iCycle System (Bio-Rad, Hercules,
CA, USA). PCR data were analyzed using GraphPad
Prism (GraphPad Software, San Diego, CA, USA). The
sequences of the PCR primers used are listed in supple-
mentary material, Table S3.
RNA-seq analysis
Total RNA was extracted from tumor tissues derived
from either Phf8-KO TRAMP mice or the control
TRAMP mice at week 37 using Trizol reagent
(Invitrogen). RNA-seq was performed by Shanghai
NovelBio Bio-Pharm Technology Co, Ltd (Shanghai,
PR China). Each sample contained pooled RNA from
three mice in each group and was mixed with an equal
mass of RNA to minimize variation across samples.
RNA-seq reads were filtered and mapped to the mouse
genome (GRCm38, NCBI) utilizing HISAT2 [29].
HTSeq was used to calculate the gene count [30].
Differentially-expressed gene analysis was applied uti-
lizing DESeq2 [31] under the following criteria: fold-
change > 2, or fold-change < 0.5; FDR < 0.05. Gene
set enrichment analysis (GSEA) was performed on the
data from the Hallmark pathway database [32]. The




SPSS 19.0 (IBM, Amonk, NY, USA) was used for all
statistical analyses. Data are presented as mean  SD.
If the data followed a normal distribution, the statistical
significance of differences between two groups of data
was analyzed by a t-test or paired t-test or χ2 test, and dif-
ferences among several groups were analyzed by one-
way analysis of variance followed by the least significant
difference procedure for comparison of means. For data
that did not fit a normal distribution, nonparametric sta-
tistical tests were used. Kendall rank correlation analysis
was used for the analysis of the correlation of the expres-
sion of PHF8 and FOXA2. A P value of less than 0.05
was considered statistically significant.
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Results
PHF8 plays an important role in NEPC development
without affecting tumor initiation
The Phf8 knockout male mice (Phf8−/y mice) were gen-
erated as described previously [33]. Consistent with the
previous observation, loss of Phf8 had no effect on either
gross morphological phenotype or fertility (data not
shown). In addition, histopathological staining of pros-
tates from 25-, 37-, and 53-week-old control C57 and
Phf8−/y male mice showed that Phf8 knockout did not
affect prostate development, suggesting that PHF8 is
not essential for prostate homeostasis under physiologi-
cal conditions (supplementary material, Figure S1A–
C). This observation was further substantiated by double
immunofluorescence staining for CK5 (a marker of basal
cells) and CK18 (a marker of luminal epithelial cells)
(supplementary material, Figure S1D–F).
The TRAMP mouse model has been widely used in
prostate cancer research because it closely mirrors the
pathogenesis of human prostate cancer. With the trans-
genic expression of viral SV40 oncoprotein in the pros-
tatic epithelium, TRAMP mice develop PIN at
10–12 weeks of age and invasive prostate adenocarci-
noma by 18–20 weeks [34,35]. In their lifetime, about
20% of TRAMPmice develop NEPC [5]. To investigate
the potential role of PHF8 in prostate cancer initiation
and progression, we crossed female Phf8 knockout mice
(Phf8X−/−) with male TRAMP mice to obtain male Phf8
knockout TRAMP mice (TRAMP/Phf8-KO). We then
compared prostate lesions in TRAMP/Phf8-KO male
mice with those of TRAMP male mice at weeks
12, 25, and 37. Prostate lesions were categorized as nor-
mal, LGPIN or HGPIN, WD-Adeno or UD-Adeno, and
analyzed as described previously [36]. Also according
to a previous study [26], we categorized UD-Adeno as
NEPC lesions, because our H&E staining revealed that
the cells in UD-Adeno lesions show NEPC-like charac-
teristics including pleomorphism, a high nuclear/cyto-
plasmic ratio, and loss of glandular differentiation.
Figure 1A–C show representative H&E stains of the
prostate lesions from control TRAMP and TRAMP/
Phf8-KO male mice at weeks 12, 25, and 37, respec-
tively, and Figure 1D–F show the corresponding lesion
status at each stage. Both LGPIN and HGPIN were
observed in both TRAMP/Phf8-WT and TRAMP/
Phf8-KO mice (n = 5) at week 12. Adenocarcinoma
lesions were observed in both groups at weeks
25 (n = 5) and 37 (n = 8), with a slight increase in
TRAMP/Phf8-KO. Interestingly, while NEPC lesions
were identified in one TRAMP/Phf8-WTmouse at week
25 (1/5) and two TRAMPmice at week 37 (2/8), none of
the TRAMP/Phf8-KO mice developed NEPC lesions
during the same time period. Even at week 42, NEPC
lesions were not found in the TRAMP/Phf8-KO mice
(n = 7, data not shown). These results indicate that
knockout of Phf8 specifically blocked NEPC develop-
ment. To further confirm our H&E results, we conducted
immunostaining for the adenocarcinoma marker AR and
the NEPC markers SYP and CD56. AR-positive adeno-
carcinomas were seen in both control and Phf8 knockout
TRAMP mice at week 25 (data not shown). However,
SYP- and CD56-positive NEPCs were seen only in the
TRAMP control with none in Phf8-KO mice at week
37 (supplementary material, Figure S2). In addition, an
abdominal cavity metastasis in one mouse at week
25 and nine metastases in three mice at week 37 (three
to the kidneys, one to the lung, two to the liver, two to
the abdominal cavity, and one to the testis) were found
in the control mice. However, no metastasis was seen
in Phf8-KO mice during the same time period. Consis-
tent with results reported previously [15], almost all the
metastatic lesions were NE carcinomas, as evidenced
by absence of staining for AR and positive staining for
SYP, CD56, and CgA (supplementary material,
Figure S3A–G). Of note, the levels of PHF8 were much
higher in the metastatic NE (supplementary material,
Figure S3H). These results taken together suggest that
PHF8 plays an important role in NEPC development
but has little to do with the initiation and development
of adenocarcinoma.
PHF8 knockout impairs the NEPC signature
To further investigate the effect of PHF8 on NEPC devel-
opment, we conducted RNA-seq on tumor tissues derived
from Phf8-KO and control TRAMP mice (data deposited
inGSE157621). This analysis identified 2092 differentially
expressed genes (fold-change > 2, or fold-change < 0.5;
FDR < 0.05) with 623 down- and 1469 up-regulated in
TRAMP/Phf8-KO mice (Figure 2A). We also compared
the expression of 32 genes from a panel of 70 genes consid-
ered as NEPC identifiers [11]; the results suggest that the
tumors derived from Phf8-KO cells more represent adeno-
carcinomas (Figure 2B). Results from gene set enrichment
analysis (GSEA) using theAR signaling signature ‘HALL-
MARK_ANDROGEN_RESPONSE’ suggest that loss of
PHF8 affected the AR signaling pathway (FDR
q = 0.043, Figure 2C), as evidenced by the alteration of
AR targets in Phf8-knockout tumors (Figure 2D). We then
conducted a bioinformatics analysis for the common
altered genes which were downregulated in Phf8-KOmice
compared with control TRAMP mice, however signifi-
cantly upregulated in NEPC patients, by using the pub-
lished dataset by Beltran et al [11]. Of note, ASCL1 and
FOXA2, two important transcriptional factors involved in
NEPC development, are among them and top ranked
(Figure 2E). Consistent with the RNA-seq results, immu-
nostaining showed that FOXA2, a transcriptional factor
important for NEPC development [15,19], was substan-
tially reduced in tumors derived from TRAMP/Phf8-KO
mice (Figure 2F).
The role of PHF8 in NEPC cell proliferation and
metastasis
Given the fact that high-grade neuroendocrine carcino-
mas including neuroblastoma, NEPC, and small-cell car-
cinomas of the lung and bladder are all more aggressive
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[37], we wanted to determine if PHF8 plays any role in
the tumor growth and invasiveness of NEPC. To do so,
we knocked down PHF8 (~70%) using specific small
hairpin RNAs (shRNAs) in AR-negative, NEPC-like
PC-3 cells (Figure 3A,B). The results in Figure 3C,D
indicate that knockdown of PHF8 inhibited both cell
proliferation and colony formation. These findings were
further substantiated by in vivo data showing that stable
knockdown of PHF8 using shRNA reduced the size
(Figure 3E), volume (Figure 3F), and weight
(Figure 3G) of the PC-3 tumor xenografts in nude mice.
Furthermore, the results from both Transwell and wound
healing assays indicate that PHF8 is capable of enhancing
migration and invasion (Figure 3H,I). Finally, we injected
PC-3 cells with (shPHF8) or without (EV) PHF8 knock-
down into the tail vein and monitored the number and size
of tumor nodules in the lungs. Metastasized nodules were
seen in the lungs of all mice (10/10, 100%)when theywere
injectedwith PC-3 cells infected by EV.However, not only
fewer but also smaller tumor nodules were observed in the
lungs of six mice (6/10, 60%) injected with PC-3 cells
infected by shPHF8 (Figure 3J). In addition, a kidney
tumor nodule was observed in one of the controls but in
none of the mice injected with PC-3 cells infected by
shPHF8 (Figure 3K). These data also support the notion
that PHF8 plays important roles in NEPC cell proliferation,
migration, and invasion. In addition, we also investigated
these effects of PHF8 on the adenocarcinoma cell line
(LNCaP). We found that the proliferation (supplementary
material, Figure S4B), invasion (supplementary material,
Figure S4C), and migration (supplementary material,
Figure S4D) of LNCaP were inhibited when PHF8 was
efficiently knocked down by shRNA (supplementary
material, Figure S4A). Conversely, PHF8 overexpression
rendered LNCaP cells resistant to anti-androgen therapy
(bicalutamide and enzalutamide treatment, supplementary
material, Figure S4G,H), accompanied by increased
expression of NSE (supplementary material, Figure S4E,
F). These observations also suggest that the function of
PHF8 is not cell type-specific.
PHF8 promotes NEPC development by
transcriptionally upregulating FOXA2
To investigate the molecular mechanism of
PHF8-regulated NEPC development, we first examined
whether PHF8 regulates the expression of transcriptional
factors and regulators that have been implicated in
NEPC development. To do so, two prostate cancer cell
lines, PC-3 and NE1.3, with NEPC phenotype were
used. When these cells were treated with PHF8-specific
small interference RNAs (siRNAs), the mRNA levels of
both PHF8 and FOXA2, but not the other genes, were
significantly downregulated (Figure 4A,B). Immuno-
blotting analysis found that transient knockdown of
PHF8 not only markedly downregulated the levels of
Figure 1. Tumorigenesis in Phf8-KO TRAMP mice. (A–C) The predominant histologic classifications of the prostatic lesions of the mice at
weeks 12 (A), 25 (B), and 37 (C). (D–F) The statistical results (χ2 test) of the histologic analysis between Phf8-WT and Phf8-KO TRAMP mice
at weeks 12(D), 25 (E), and 37 (F).
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PHF8 and FOXA2 but also led to substantial reductions
of the NEPC markers SYP, CD56, and CgA (Figure 4C,
D). In addition, immunofluorescence assays showed that
FOXA2 and PHF8 were co-localized in nuclei, and
reduced levels of FOXA2 were seen in PHF8 knock-
down cells (Figure 4E). Consistent with this, IHC stain-
ing also showed reduced FOXA2 and NEPC markers
(SYP and CD56) in tumors derived from PC-3 cells with
shRNA-mediated PHF8 knockdown (Figure 4F). Since
knockdown and overexpression of PHF8 down- and
up-regulated the FOXA2 promoter-regulated luciferase
activity, respectively (Figure 4G,H), we conclude that
PHF8 regulates FOXA2 expression transcriptionally.
More importantly, the chromatin immunoprecipitation
assay showed that PHF8 knockdown also reduced
PHF8 occupancy of the FOXA2 promoter, with a con-
current increase of repressive histone markers
H3K9me1, H3K9me2, H3K27me2, and H4K20me1 in
the promoter region of the FOXA2 gene (Figure 4I), sug-
gesting that PHF8 upregulates FOXA2 expression in a
demethylase activity-dependent manner. Finally, we
demonstrated that overexpressed FOXA2 in PC-3 and
NE1.3 cells infected with shPHF8 is capable of rescuing
the NEPC markers SYP, CgA, and CD56 (Figure 4J,K),
as well as the reduced cell viabilities induced by PHF8
knockdown (Figure 4L,M), indicating that PHF8 pro-
motes NEPC development primarily, or at least in part,
by upregulating FOXA2.
PHF8 and FOXA2 can serve as biomarkers of NEPC
To explore the clinical significance of PHF8 in NEPC,
we first analyzed genetic alterations of PHF8 in the pub-
licly available large-scale database ‘The Cancer Genome
Atlas’ (TCGA; http://www.cbioportal.org) and found
that ~30% patients in the NEPC cohort have PHF8
amplification (Figure 5A), providing a molecular expla-
nation for the elevated levels of PHF8 in NEPC.We then
compared the levels of PHF8 and FOXA2 in seven
paired-prostate cancer specimens collected before and
Figure 2. Phf8 knockout inhibits the NEPC signature. (A) Heatmap of global altered gene expression in Phf8-KO TRAMP mice compared with
control TRAMP mice. (B) Heatmap of a selected gene cluster from an integrated 70-gene NEPC classifier revealed by Beltran et al [11] in both
groups. (C) GSEA enrichment plot of the HALLMARK_ANDROGEN_RESPONSE gene set in the above-mentioned mice. (D) Heatmap of AR tar-
get gene expression in both groups. (E) Venn diagram revealing the commonly altered genes which were downregulated in Phf8-KO mice
compared with control TRAMP mice but significantly upregulated in NEPC patients, by using Beltran et al’s published dataset [11].
(F) Immunostaining for FOXA2 in the prostate samples from Phf8-KO TRAMP mice and control TRAMP mice (non-parametric test).
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after treatments with abiraterone, enzalutamide or doce-
taxel. Of note, immunostaining showed that all seven
tumors were adenocarcinomas before the treatment, evi-
denced by staining positive for both AR and PSA, and
staining negative for SYP, CD56, and CgA, whereas
most of them became AR- and PSA-negative, and
SYP-, CD56-, and CgA-positive after ADT (supplemen-
tary material, Figure S5A). The representative immunos-
taining (Figure 5B) and the summarized results
(Figure 5C,D) showed elevated levels of both PHF8
and FOXA2 in ADT-induced NEPC. To further substan-
tiate this notion, we compared the levels of PHF8 and
FOXA2 in different patient-derived xenograft (PDX)
samples by IHC. To avoid any experimental variations,
we placed NEPC-type (characterized by staining posi-
tive for SYP, CD56, and CgA, and staining negative
for AR) PDX specimens and adenocarcinoma-type
(characterized by staining negative for SYP, CD56,
and CgA, and staining positive for AR; supplementary
material, Figure S5B) patient samples on the same slide
Figure 3. shRNA-mediated PHF8 knockdown inhibits the proliferation, invasion, and migration of prostate cancer. (A, B) The expression of
PHF8 was examined by (A) immunoblotting and (B) RT-qPCR after PHF8 knockdown in PC-3 by shRNA with empty vector as the control.
(C) PC-3 cells infected with EV or shPHF8 were seeded in 96-well plates and cell numbers were estimated using CCK-8 at days 0, 1, 2, 4,
and 6. (D) PC-3 cells with or without PHF8 knockdown (shRNA) were seeded in six-well plates with 1000 cells per well. Cells were fixed with
methanol and stained with crystal violet. (E–G) The sizes of the tumors from mice bearing EV- and shPHF8-infected PC-3 xenografts were
recorded every 2 days (E) and imaged using a whole-body fluorescence imaging system before sacrifice (F). The tumors were collected and
weighed (G). (H) PC-3 cells with or without PHF8 knockdown (shRNA) were seeded in 24-well Transwell chambers with or without Matrigel
and cultured for 24 h. Cell invasion andmigration were estimated. (I) PC-3 cells with or without PHF8 knockdown (shRNA) were seeded in six-
well plates and cell migration was estimated by scratch-wound healing assay. (J, K) PC-3 cells with or without PHF8 knockdown (shRNA) were
injected via the tail-vein and the lungs (J) and the kidneys (K) were harvested and sections H&E-stained. A t-test was used.
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and conducted immunostaining with antibodies against
PHF8 and FOXA2. Supplementary material, Figure S5
shows that the levels of both PHF8 and FOXA2 in
NEPC lesions are much higher than those in the adeno-
carcinoma. Similarly, the levels of PHF8 and FOXA2
in NEPC were also higher than those in CRPC when
similar experiments were conducted with the NEPC
PDX (LTL-545) and the CRPC PDX tissues (LTL-
313HR, characterized by staining negative for SYP,
CD56, and CgA, and staining positive for AR). Finally,
the IHC scores of the PHF8 and FOXA2 staining in
59 adenocarcinoma, 13 CRPC-Adeno, and 10 NEPC
or NED specimens indicate that expression of PHF8
(Figure 5E) and FOXA2 (Figure 5F) in NEPC tissues
Figure 4. PHF8 regulates FOXA2 expression and transcription. (A, B) The mRNA levels for several transcription factors involved in NEPC devel-
opment were estimated by RT-PCR after PHF8 knockdown by siRNA with scrambled siRNA (siScr) as the control in (A) PC-3 and (B) NE1.3 cells
(non-parametric test). (C, D) The expression of FOXA2 and NEPC markers (SYP and CD56) was examined by immunoblotting after siRNA-
mediated PHF8 (siPHF8) knockdown in (C) PC-3 and (D) NE1.3 cells. (E) Double immunofluorescence staining analysis of PHF8 and FOXA2
was conducted after PHF8 knockdown by using siRNA. The knockdown cell is indicated by the red arrow. (F) Immunostaining for FOXA2
and NEPC markers (SYP and CD56) in xenografts of PC-3 cells with or without PHF8 knockdown (shRNA) (non-parametric test). (G, H)
PC-3 cells with or without PHF8 knockdown (shRNA) were transfected with a FOXA2-Luc construct and Renilla luciferase vector, as well
as indicated plasmids. Cell lysates were collected to investigate the expression of PHF8 (G) and measure luciferase activity after 48 h trans-
fection (H) (non-parametric test). (I) PC-3 cells with or without PHF8 knockdown (shRNA) were subjected to CHIP assays with PHF8,
H3K9me1, H3K9me2, H3K27me2, and H4K20me1 antibodies. The immunoprecipitated materials were used for qPCR analyses of the pro-
moter regions of FOXA2 (t-test). (J, K) NEPC markers including SYP, CgA, and CD56 were estimated by western blot when FOXA2 was over-
expressed in PHF8 KD (shRNA) PC-3 (J) and NE1.3 (K) cells. (L, M) CCK-8 assays were used to investigate the cell viabilities after 24 h of cell
culture when FOXA2 was overexpressed in PHF8 KD (shRNA) PC-3 (L) and NE1.3 (M) cells (non-parametric test).
PHF8 in NEPC progression 9
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2020; 00: 000–000
www.thejournalofpathology.com
is much higher than in adenocarcinoma (Adeno) and
CRPC-Adeno tissues. These findings are in concordance
with the expression of PHF8 and FOXA2 found in
NEPC and CRPC samples in the public dataset of Bel-
tran et al [11] (supplementary material, Figure S6A,B).
Furthermore, the expression of PHF8 positively corre-
lated with that of FOXA2 (supplementary material,
Figure S6C). In addition, we investigated the association
of the expression of PHF8 and FOXA2 with pathologi-
cal grade (Gleason scores) in 42 specimens with prostate
adenocarcinoma (supplementary material, Figure S6D–
H). Our results revealed that compared with lower-grade
tumors (Gleason score less than or equal to 7), the levels
of both PHF8 (supplementary material, Figure S6D–F)
and FOXA2 (supplementary material, Figure S6E–G)
were significantly higher in tumors with higher Gleason
scores (>7). More importantly, a positive correlation
between the levels of PHF8 and FOXA2 in prostate ade-
nocarcinoma samples is revealed by correlation analyses
(supplementary material, Figure S6H) and this finding is
further substantiated by the heatmap (supplementary
material, Figure S6I), which reflects the relationship
between the levels of PHF8 and FOXA2 as well as their
expression and the degree of malignancies. Since the
levels of PHF8 and FOXA2 are higher in NEPC and pos-
itively correlated with each other, we propose that the
elevated levels of PHF8 and FOXA2 can either individ-
ually or in combination serve as NEPC diagnostic
biomarkers.
Discussion
Our current research identified a previously unknown
PHF8/FOXA2 axis in prostate cancer as well as its role
in NEPC development. Since knocking out Phf8 had
minimal effect on the initiation and progression of pros-
tate adenocarcinoma but abrogated both the initiation
and the metastasis of NEPC, we conclude that PHF8
Figure 5. PHF8 and FOXA2 expression in adenocarcinoma and NEPC of patients’ specimens. (A) Genetic changes of PHF8 in prostate cancer
from the BioPortal database. (B) Immunostaining for PHF8 and FOXA2 in the same patient before and after ADT. (C, D) Statistical results of the
IHC scores for (C) PHF8 and (D) FOXA2 in B (paired t-test). (E, F) Immunostaining for PHF8 (E) and FOXA2 (F) in adenocarcinoma, CRPC-Adeno,
and NEPC or NED samples (non-parametric test).
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plays a unique role in NEPC development. Based on the
fact that PHF8 upregulates FOXA2 transcriptionally by
demethylating and removing the repressive histone
marks in the promoter region of the FOXA2 gene and
that overexpressed FOXA2 is capable of rescuing NEPC
phenotype, we proposed a working model to illustrate
the role of the PHF8/FOXA2 axis in NEPC development
(Figure 6). Since both PHF8 and FOXA2 are highly
expressed in NEPC cells, we suggest that the levels of
PHF8 and FOXA2 can either individually or in combi-
nation serve as NEPC biomarkers, and that targeting
either PHF8 or FOXA2 could be potential therapeutic
strategies for NEPC treatment. However, the prognostic
values of PHF8 and FOXA2 in NEPC patients need to be
further investigated by using larger cohorts of samples.
Multiple factors including AURKA, MYCN, BRN2,
SRRM4, REST, EZH2, and FOXA2 have been impli-
cated in the development of NEPC. For example, both
AURKA and MYCN are elevated in NEPC and they
function cooperatively to promote NEPC [13]. It is also
well established that AR-repressed BRN2 can induce
neuroendocrine differentiation in both castration- and
enzalutamide-resistant prostate cancer models [14].
The RNA splicing factor SRRM4 is capable of driving
adenocarcinoma cell progression toward NEPC with
concurrent upregulation of NEPC-specific biomarkers
[38]. On the other hand, both REST and EZH2 are
involved in NEPC progression by epigenetic modifica-
tion of the genome [17,18]. Although FOXA2 appeared
to be involved in NEPC development, the underlying
molecular mechanism was unknown. By using different
model systems including combined Phf8 knockout and
the TRAMP mouse model, NEPC cell lines, NEPC
PDX and patients’ cancer tissues, we established the
PHF8/FOXA2 axis and illustrated its role in NEPC
development. We noticed that results from previous
research using LNCaP cells suggest that PHF8 promotes
CRPC but suppresses neuroendocrine differentiation
[36]. The discrepancy between our findings and previ-
ously reported results could be the use of different cell
lines and experimental systems. In the TRAMP model
system, PHF8 plays an indispensable role in NEPC
development, although knocking out Phf8 has minimal
effect on the development of adenocarcinoma.
Therefore, the mechanisms in androgen depletion-
induced NED of LNCaP cells could be different from
those in NEPC development in the TRAMP model and
further research will reconcile these differences. The
TRAMP mouse model has some inherent limitations
because the viral antigens are not naturally associated
with human prostate cancer and the model would
develop some extensive neuroendocrine tumors sponta-
neously different from the development of human NEPC
[5]. Nevertheless, the TRAMP model is still a useful
means to investigate the molecular mechanism underly-
ing the progression of NEPC because the formation of
NEPC in TRAMP mice partially resulted from the inac-
tivation of p53 and RB1, crucial events happening dur-
ing the NED of human prostate cancer [12].
Although we demonstrated a critical role of PHF8 in
NEPC development, there are many unanswered ques-
tions. For example, increased expression of PHF8
enhanced NEPC development by epigenetically upregu-
lating the transcription factor FOXA2, but the cause of
PHF8 upregulation is elusive. It has been reported
recently that lineage tracing experiments in TRAMP
mice showed that NEPC might originate from the
p63-positive basal cells instead of the pre-existing ade-
nocarcinoma cells [7]. Whether upregulated PHF8 has
anything to do with these basal cells is unknown. On
the other hand, Phf8 knockout completely inhibited the
NEPC development in TRAMP mice without affecting
the development of CK5-positive basal cells in C57
mice; whether PHF8 affects malignant transformation
of basal cells needs to be further investigated. Further-
more, PHF8 upregulates FOXA2 by erasing repressive
histone markers. It is unclear if PHF8 interacts with the
chromosome directly or through other transcriptional
factors indirectly. Further analyses using tools from the
GeneCards website (https://www.genecards.org/) sug-
gest that the transcriptional factors TCF4 and REST
could be involved in the regulation of FOXA2. It has
also been reported that β-catenin is recruited to the
TCF/LEF-binding site in the promoter region of FOXA2
[39] and our preliminary data indicate that PHF8 can
complex with β-catenin (data not shown). In addition,
it has been reported that PHF8 and REST can co-occupy
the same chromosome regions. These lines of evidence
Figure 6. Schematic illustration of the proposed model in which PHF8 regulates FOXA2 and NEPC development.
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suggest that PHF8 could upregulate FOXA2 by com-
plexing with either REST or β-catenin/TCF4 and subse-
quently erasing the repressive histone marks on the
promoter region of the FOXA2 gene.
In summary, by using transgenic and knockout mice,
in vitro cell lines, and in vivo xenografts, as well as
NEPC PDX and patients’ tissue samples, we revealed a
critical role of the epigenetic regulator PHF8 in NEPC
development, rendering PHF8 a potential therapeutic
target for the deadly NEPC.
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